Chelation Partners

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Chelation Partners is focused on medical indications related to iron availability such as infectious disease, AMR & cancer. Chelation's lead product candidate DIBI is an ultra-potent, non-toxic, iron-binding polymer. Published studies of DIBI show single µM MICs (minimal inhibitory concentration) for bacteria and fungi in models of infection, including pneumonia, MRSA and sepsis, and potential synergistic benefits when administered with conventional anti-infective agents.

DIBI has potential COVID-19 therapeutic applications: direct SARS-CoV-2 antiviral effects through iron sequestration and/or receptor modulation and potential reduction in COVID-19 mortality due to benefits of DIBI on cytokine storm and secondary pneumonia. The company has recently enhanced its team with anti-infective drug development expertise and is pivoting near term efforts to focus DIBI for COVID-19 pandemic response and will be raising $5M in the near future with a larger raise expected in the next 12 months.
Company Type:
Company Website:
Company HQ State:
Nova Scotia
Company HQ Country:
Canada
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
DIBI
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Executive Chairman
Chelation Partners